期刊文献+

Chk1及其抑制剂在肿瘤中的作用

The role of Chk1 and its inhibitors in tumor
原文传递
导出
摘要 细胞周期检查点激酶1(checkpoint kinase 1,Chk1)是一种在细胞周期内对受损DNA起重要作用的蛋白激酶,可以对DNA进行及时修复,来保证进入有丝分裂前的基因完整性。Chk1表达的高低与肿瘤的发生发展有密切关系,基于Chk1在细胞周期中的独特作用机制,目前有大量Chk1抑制剂正在进行研究。本文综述了Chk1的作用机制,及其与肿瘤的关系,以及近些年来Chk1抑制剂的临床研究。 Checkpoint kinase 1(Chk1)is a protein kinase,which plays an important role in repairing damaged DNA timely during the cell cycle,ensuring the integrity of gene before entering into the mitosis.The expression of Chk1 is closely associated with the occurrence and growth of the tumor.Based on the Chk1’s unique mechanism,a large number of studies about Chk1 inhibitors is ongoing.This review discussed not only the mechanism of Chk1,but also the relation between Chk1 and tumor,and clinical studies about Chk1 inhibitors in recent years.
作者 岳厚汝 薛佳兴 易俊希 徐尧 焦炳华 卢小玲 YUE Houru;XUE Jiaxing;YI Junxi;XU Yao;JIAO Binghua;LU Xiaoling(16th Cadet,Naval Medical University Student Brigade,Shanghai 200433,China;Department of Biochemistry and Molecular Biology,Naval Medical University,Shanghai 200433,China)
出处 《生命的化学》 CAS CSCD 2020年第10期1738-1750,共13页 Chemistry of Life
基金 国家重点研发计划项目(2019YFC0312504)。
关键词 CHK1 作用机制 肿瘤 抑制剂 Chk1 action mechanism tumor inhibitors
  • 相关文献

参考文献7

二级参考文献39

  • 1Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China.Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J].Hepatobiliary & Pancreatic Diseases International,2012,11(5):458-466. 被引量:29
  • 2王玉祥,祝淑钗,王鑫,封巍,李娟,沈文斌.CHK1和CHK2在食管癌组织中的表达[J].肿瘤防治研究,2006,33(3):171-174. 被引量:10
  • 3段磊,黄建梅,杨春澍,马长华.厚皮香八角果皮的化学成分研究[J].中国药学杂志,2006,41(6):411-413. 被引量:10
  • 4史社坡,蒋丹,董彩霞,屠鹏飞.东北铁线莲化学成分研究[J].中草药,2007,38(3):335-337. 被引量:34
  • 5Venkatesha VA, Parsels LA, Parsels JD, et al. Sensitization of pancreatic cancer stem cells to gemc-itabine by Chkl inhibition[J]. Neoplasia, 2012,14(6):519-525.
  • 6Bartek J, Lukas J. Chkl and Chk2 kinase in checkpoint control and cancer[J]. Cancer Cell, 2003,3(5):421-429.
  • 7Senderowicz AM. Novel direct and indirect cyclin- dependent kinase modulators for the prevention and treatment of human neoplasms[J]. Cancer Chemother Phar- macol, 2003, 52(Suppl):S61-S73.
  • 8Verlinden L, Vande Bempt I, Eelen G, et al. The E2F- regulated gene Chkl is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas[J]. Cancer Res, 2007,67(14):6574-6581.
  • 9Matsumoto K, Nagahara T, Okano J, et al. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracelluar signal-regulated and checkpoint kinases [J]. Oncol Rep, 2008,20(4):863-872.
  • 10Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pan-creatic cancer cells[J]. Mol Cancer Ther, 2009, 8(1):45-54.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部